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Aberrant ERK 1/2 complex activation and





Background: Fatal neurodegenerative disorders such as Creutzfeldt-Jakob and Gerstmann-Sträussler-Scheinker
diseases in humans, scrapie and bovine spongiform encephalopathy in animals, are characterized by the
accumulation in the brain of a pathological form of the prion protein (PrP) denominated PrP
Sc. The latter derives
from the host cellular form, PrP
C, through a process whereby portions of its a-helical and coil structures are
refolded into b-sheet structures.
Results: In this work, the widely known in vitro model of prion replication, hypothalamic GT1-1 cell line, was used
to investigate cellular and molecular responses to prion infection. The MAP kinase cascade was dissected to assess
the phosphorylation levels of src, MEK 1/2 and ERK 1/2 signaling molecules, both before and after prion infection.
Our findings suggest that prion replication leads to a hyper-activation of this pathway. Biochemical analysis was
complemented with immunofluorescence studies to map the localization of the ERK complex within the different
cellular compartments. We showed how the ERK complex relocates in the cytosol upon prion infection. We
correlated these findings with an impairment of cell growth in prion-infected GT1-1 cells as probed by MTT assay.
Furthermore, given the persistent urgency in finding compounds able to cure prion infected cells, we tested the
effects on the ERK cascade of two molecules known to block prion replication in vitro, quinacrine and Fab D18. We
were able to show that while these two compounds possess similar effects in curing prion infection, they affect
the MAP kinase cascade differently.
Conclusions: Taken together, our results help shed light on the molecular events involved in neurodegeneration
and neuronal loss in prion infection and replication. In particular, the combination of chronic activation and
aberrant localization of the ERK complex may lead to a lack of essential neuroprotective and survival factors.
Interestingly, these data seem to define some common traits with other neurodegenerative disorders such as, for
example, Alzheimer’s disease.
Background
Transmissible spongiform encephalopathies (TSE) or
prion diseases, such as Creutzfeldt-Jakob disease, Gerst-
mann-Sträussler-Scheinker syndrome and fatal familial
insomnia in humans, bovine spongiform encephalopathy
and scrapie in animals, are a group of incurable neuro-
degenerative disorders. TSE can manifest as sponta-
neous, inherited and infectious maladies. These diseases
are caused by the accumulation of prions in the central
nervous system (CNS).
Prions are novel infectious agents composed solely of
a pathological isoform of the prion protein (PrP) PrP
Sc,
derived from the host-encoded, cellular form of PrP,
PrP
C [1]. PrP
Sc accumulation is driven by a conversion
event in which a-helix and random coiled structures are
refolded into b-sheets [2]. The PrP
C molecule is a mem-
brane glycoprotein highly expressed in neurons and is
linked to the outer leaflet of neuronal membranes via
glycosylphosphatidylinositol moiety localized in choles-
terol-rich domains called “rafts”.D e s p i t eP r P
C being
conserved amongst mammals, its function is still ambig-
uous and defining the cellular processes involved in
prion disease remains one of the main challenges in
Prion Biology.
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0/0) do not show gross phe-
notypic abnormalities [3], analysis of in vitro models of
primary cells derived from Prnp
0/0 revealed a dysmeta-
bolism of copper and an increased susceptibility to oxi-
dative stress [4], suggesting the involvement of PrP
C in
redox homeostasis and in copper uptake within the cell.
Additional studies revealed a role for PrP
C in cellular
adhesion, showing that PrP interacts with neural cell
adhesion molecules (N-CAMs), laminin and laminin
receptor [5,6].
Moreover, PrP
C can regulate neurite outgrowth [7]
and neuroprotection [8] in primary cultures of neurons.
These two latter effects rely on the interaction of PrP
with stress-inducible protein 1 (ST1) and seem to be
mediated by distinct signaling pathways [9]. These dif-
ferent lines of experimental evidence suggest that PrP
C
may also transduce signals from the membrane to the
nucleus. It has been established that PrP
C mediates acti-
vation of cAMP/protein kinase A (PKA) in retinal tissue
[10] and activation of protein kinase C (PKC) in
embryonic rat hippocampal neurons [7]. Moreover, PrP
C
seems to be involved in regulation of calcium-mediated
cellular events [11]; in Prnp
0/0 mice a decrease of cal-
cium influx via VGCC was found, suggesting a func-
tional interaction with calcium channels on the cell
membrane [12]. Furthermore, in prion-infected neuro-
blastoma cells a decrease in receptor-mediated calcium
responses was observed [13]. In addition, PrP
C has been
recently identified as an amyloid-b-oligomer receptor
and it appears to mediate impairment of synaptic plasti-
city in Alzheimer’s disease (AD) [14]. Among others,
also mitogen-activated protein kinases (MAPKs) path-
ways seem to be regulated by PrP
C. These signaling cas-
cades are strongly conserved in eukaryotic cells and
modulate molecular events involved in cell differentia-
tion, proliferation and apoptosis, and in gene expression
and inflammation [15] processes, whose deregulation
plays a crucial role in neurodegenerative diseases such
as TSE. All these cascades are composed of three dis-
tinct modules: MAP kinases, MAPK kinases and
MAPKK kinases. In mammals, four sets of MAPKs are
expressed: extracellular signal-related kinases (ERK),
Jun-amino terminal kinases (JNK), p38 proteins and
ERK5 [16]. These cascades have been observed in sev-
eral cellular models linked to PrP biology. By mimicking
the binding of a cellular interactor by antibody mediated
cross-linking, a PrP-dependent fyn activation was
observed in 1C11 cells [17]. Using a similar approach,
ERK1/2 pathway activation was observed in GT1-7 cells
[18]. In monocytes, ERK activation was obtained using
PrP fusion protein with a Fc domain [19]. The treatment
of hippocampal neurons in culture with either hop/STI1
or hop/STI1230-245 also led to ERK activation [9]. The
same results were obtained developing retinal tissues
using binding molecules for PrP
C [10]. Hyper-activation
of several MAP kinases was observed in hamster brains
infected with 263 K scrapie strain [20], and elevated
levels of the src family kinases were found in an in vitro
model and two different in vivo models of prion disease
[21]. Recent studies have linked the increased level of
phosphorylation of the MAP kinases pathway to a neu-
roprotective and antiapoptotic effect towards toxicity of
PrP
Sc [22]. In contrast, in a model of prion disease using
prion peptide 106-126, the overstimulation of ERK path-
way was correlated with oxidative injury in GT1 cells
throughout ROS production [23]. According to this
model oxidative stress plays a central role in neurode-
generative diseases [24].
In this study we used a neuronal cell model, GT1-1
hypothalamic cell line [25], known to support a sus-
tained prion replication. To investigate cell response to
prion infection, we focused on MAP kinases. In particu-
lar we dissected the ERK pathway, analyzing the levels
of phosphorylation of key molecules such as src, MEK
and ERK before and after prion infection, both de novo
and chronic. We then mapped the distribution of phos-
pho-ERK within the different cellular compartments in
infected and uninfected cells. For the first time we
showed how prion infection has the capacity of altering
the levels of activation and the cellular localization of
the ERK complex, affecting cell proliferation. In addi-
tion, cells were treated with Fab D18 [26] and quina-
crine [27], two molecules known to cure prion infection
in cell culture, and assessed for the extent of phosphory-
lation activation. Our findings show how the two com-
pounds exert different effects on the ERK pathway,
suggesting that the two molecules may interfere with
prion infection via different pathways.
Results
Scrapie infection affects MAP kinases levels in GT1 cells
In recent years several cell systems permissive to the
replication of different mouse-adapted prion strains
have been developed [28]. They represent a suitable tool
for studying the molecular basis of prion-induced neuro-
degeneration; their simplicity, in fact, allows to analyze
the events occurring during prion pathogenesis much
better than in vivo models.
To investigate the response of neurons towards prion
infection we chose, as a model of prion replication, an
immortalized murine cell line derived from hypothala-
mic cells either uninfected or chronically infected with
RML prion strain (GT1 cells and ScGT1 cells respec-
tively, hereafter). In order to elucidate some of the
mechanisms leading to neuronal loss we focused on
MAP Kinase pathways, given their pivotal role in cell
growth and survival. We dissected one of the pathways,
the ERK cascade, and, in particular, we analyzed the src
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posed of proteins located at the early stages of the ERK
cascade, next to the inner leaflet of the cellular mem-
brane. The MEK1/2 protein complex is the physiological
activator of ERK1/2, that, in turn, upon activation, can
either enter the nucleus and start the gene expression
process, or be retained in the cytoplasm to activate
other signaling molecules (Fig. 1).
Total cell extracts from GT1, both uninfected and
infected (Fig. 2), were tested for phosphorylation levels
of the kinases. In ScGT1 cells, scrapie infection led to a
general overstimulation of the ERK cascade. Immuno-
blot revealed a statistically significant increase of phos-
pho-ERK levels in ScGT1 compared to uninfected cells,
whilst a decrease was detected in the level of phospo-
MEK upon prion infection (Fig. 3A). Instead, the densi-
tometric analysis between the levels of phospho-src in
infected and uninfected cells revealed an increased phos-
pho-src signal in ScGT1 (Fig. 3A).
The activation of ERK pathway was also tested in de
novo infected cells. GT1 cells were infected as described
in the Materials and Methods section, and tested at the
fourth passage upon infection (Fig. 1). De novo infected
GT1 cells (iGT1) showed a statistically significant
increase of phospho-ERK and phospho-MEK levels com-
pared to mock infected cells (cGT1) (Fig. 3B). On the
contrary, the levels of phospho-src were found strongly
decreased in iGT1 cells in compared to cGT1 cells
(Fig. 3B).
Altered phosphorylation levels upon Fab D18 and
quinacrine treatments
To date an effective cure for prion disease has not been
found, although several compounds are known to block
prion replication at least in vitro. Considering those as
models for the development of new therapeutic strate-
gies, we studied the actions of two of them, Fab D18
and quinacrine, on the ERK pathway in order to evalu-
ate their side effects on cell physiology.
We treated both infected and uninfected cells for six
days with Fab D18 at the final concentration of 50 nM
and with quinacrine at the concentration of 1 μM,
according to tested concentrations available in the litera-
ture [26,27]. The PrP
Sc signal was no longer present in
ScGT1 cells after the Fab and drug treatments as ascer-
tained by Western blot (Fig. 4). Next, we analyzed the
levels of phosphorylation of src, MEK and ERK kinases,
both before and after the treatments.
Following Fab D18 treatment, no significant variations
of phospho-ERK levels were found either in ScGT1 or
GT1 cells, whereas a significant decrease in D18 treated
GT1 was found with regards to phospho-MEK levels
Figure 1 Schematic representation of ERK pathway. PrP
C on the
cellular surface assembles a signaling platform with src family
proteins. Upon activation, this molecular complex modulates the
activity of ERK cascade. Src proteins activate MAP/ERK Kinase 1/2
(MEK1/2). The active forms of MEK1/2 complex can phosphorylize
the Extracellular signal-Regulate Kinase 1/2 (ERK1/2) that either
enters the nucleus and starts gene expression, or remains within the
cytosol.
Figure 2 Chronic and de novo infection of GT1 cell line.G T 1
cells were infected according to the procedures described in the
Materials and Methods section. Regarding de novo infected GT1
cells (iGT1) the presence of PrP
Sc was tested at the fourth passage.
PrP
Sc was detected by PK digestion assay (PK+ lanes) and the signal
revealed using Western blot technique. Approximately 20 μgo f
total protein were loaded as control (PK-lanes).
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antibody seemed to significantly decrease the level of
phospho-src, both in infected and uninfected GT1 cells
(Fig. 5A). Upon quinacrine treatment, the levels of phos-
pho-ERK were unaffected in ScGT1 cells, whilst drug
incubation increased the levels of phospho-ERK in non-
infected GT1 cells (Fig. 5B). With regards to phospho-
MEK levels, quinacrine increased its levels in ScGT1
cells, but not in GT1 (Fig. 5B). Considering the src
family activation, levels of phospho-src were strongly
decreased in ScGT1 upon quinacrine treatment, whilst
the drug was found to have no effect on src family acti-
vation in GT1 cells (Fig. 5B).
Cellular localization of phospho-ERK
When analyzing the action of the ERK pathway, it can
be noted that besides being biochemically regulated
through the phosphorylation of its kinases, the
Figure 4 Effect of D18 and quinacrine treatments on PrP
Sc
levels in ScGT1 cells. RML infected GT1 were treated for 6 days
with 1 μM quinacrine and 50 nM D18. Cell lysates were digested
with proteinase K (PK, PK+ lanes) as described in Materials and
Methods and PrP
Sc content was detected by Western blot. Twenty
μg of total proteins (PK-lanes) were loaded as control. Noticeably,
PK-resistant PrP was completely cleared in GT1 cells.
Figure 3 Analysis of ERK pathway in chronic and de novo infected GT1 cells. Approximately 20 μg of total proteins were resolved on 12%
polyacrylamide gels to detect the levels of phosphorylated forms of ERK 1/2, MEK 1/2 and src family proteins. The total amount of the same
proteins was determined as a control. Prions induced a general hyper-activation of ERK cascade in chronic infected GT1 cells (ScGT1) compared
to uninfected cells (GT1). Levels of phospho-ERK and phospho-src proteins increased upon prion infection, whilst a decrease was found in levels
of phospho-MEK (panel A). In de novo infected cells (iGT1) the levels of phospho-ERK and phospho-MEK were increased compared to mock-
infected ones (cGT1), whilst a decrease of phospho-src was detected upon prion infection (panel B). Statistics were performed using Student’s
T-test on a set of three independent experiments; data were normalized on the total amount of proteins. * P < 0.05, ** P < 0.01 versus
uninfected cells.
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compartments plays a pivotal role in establishing the
correct signaling. Upon phosphorylation, in fact, the
ERK complex can either be found in the nucleus, or
selectively retained within the cytosol. We therefore
mapped the cellular distribution of phospho-ERK by
means of immunocytofluorescence, aiming at further
elucidating the various mechanisms occurring in prion-
infected cells.
Both chronically infected, and uninfected, D18 and
quinacrine treated and untreated cell lines, were fixed
and stained according to the procedures in the Materials
and Methods section, and phospho-ERK localization was
investigated by confocal microscopy.
The pattern of phospho-ERK distribution for ScGT1
consisted in a granular dispersion of punctuate labeling
localized within the cytoplasm, more pronounced in the
perinuclear area, whilst in GT1 cells phospho-ERK
staining was equally divided between the cytosol and the
nucleus (Fig. 6A). The treatment with both Fab D18 and
quinacrine seemed to increase the fraction of phospho-
ERK localized in the nuclear compartment in treated
ScGT1 (Fig. 6A), while an opposite effect was detected
in treated uninfected GT1cells (Fig. 6A). Statistical ana-
lysis was carried out as described in the Materials and
Methods section (Fig. 6B).
Prion infection affects cell proliferation
As ERK cascade is involved in cell growth and survival; in
order to correlate the molecular findings about aberrant
signaling with defined physiologic effects, the cell prolif-
eration for both ScGT1 and GT1 was monitored before
and after the treatment with Fab D18 and quinacrine by
means of MTT assay. Without treatment a 40% lower
Figure 5 Effect of D18 and quinacrine treatment on ERK pathway in GT1 cells. Infected and uninfected GT1 cells were treated with Fab
D18 (50 nM) or quinacrine (1 μM) for 6 days; approximately 20 μg of total proteins were loaded onto 12% polyacrylamide gel and assessed for
the levels of the phosphorylated forms of ERK 1/2, MEK 1/2 and the src family proteins. The total amount of the same proteins was determined
as a control. Fab D18 did not appear to induce any significant changes in the levels of phospho-ERK both in infected and uninfected GT1, whilst
decreased levels of phospho-MEK were detected in GT1 cells upon D18 treatment (panel A). Regarding phospho-src proteins, increased levels
were found in treated GT1 compared to untreated cells, both infected and uninfected (panel A). On the contrary, quinacrine treatment induces a
significant hyper-stimulation of the ERK protein in GT1 cells and even increases the levels of the phospho-MEK in ScGT1 (panel B). Moreover, a
strong decrease on phospho-src levels were found in infected GT1 upon drug treatment (panel B). Statistics were performed using Student’sT -
test on a set of three independent experiments; data were normalized on the total amount of proteins. * P < 0.05, ** P < 0.01 versus untreated
controls, both for infected and uninfected cells.
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uninfected cells (Fig. 7). Following treatment with Fab
D18 (50 nM) and quinacrine (1 μM), cells were tested for
proliferation, again in the presence of the two com-
pounds at the same concentrations. MTT assay did not
show any significant effects on cell growth of both
ScGT1 and GT1 after the two treatments (Fig. 7).
Discussion
Prion infection hyper-stimulates ERK cascade
Whilst the pathological mechanism of prion diseases
remains elusive, many lines of evidence indicate that
prion infection may dramatically alter the physiology of
the cell. Therefore, the focus of our work consisted in
studying molecular signaling molecules in both healthy
Figure 6 Immunolocalization of phospho-ERK 1/2 within GT1 cells. Infected and uninfected GT1 cells, both D18 and quinacrine treated and
untreated, were fixed and immunostained with an antibody specific for the phosphorylated (Thr202/Tyr204) form of ERK 1/2 (in green); nuclei
were counterstained with DAPI (in blue). Merged images are shown on the left. In ScGT1 phospho-ERK appears prevalently localized within the
cytoplasm, whilst in GT1 cells the phospho-ERK staining is equally distributed between the cytosolic and the nuclear compartments (panel A).
The treatments with both Fab D18 and quinacrine induce the active form of ERK to localize preferentially within the nuclear compartment in
ScGT1, but have opposite effects on the phospho-ERK distribution in uninfected GT1 (panel A). As positive control, cells were treated with TPA
(12-O-Tetradecanoylphorbol-13-Acetate) diluted in DMSO at the concentration of 200 nM for 30 minutes. As negative control, U0126 (10 μMi n
DMSO) was used, treating cells for 1 hour (panel A). Images are representative of at least three independent experiments of immunostaining.
Scale bars, 20 μm. The quantitative analysis was carried out measuring the average intensity of fluorescence in a region of interest (ROI) of 144
pixels, both in the nuclear and cytoplasmatic regions. The histograms (panel B) show the ratio between the average intensity of fluorescence of
phospho-ERK signal in the cytosol, over the average intensity of the same signal in the nucleus. More than 100 cells were analyzed for each
condition. Statistics were performed using Student’s T-test on a set of three independent experiments; *** P < 0.001.
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neuronal model, the murine immortalized hypothalamic
GT1 cell line, able to sustain both de novo and chronic
prion infection.
First, we analyzed the effect of prion infection in
chronic infected cells. In particular, we assessed the
ERK cascade, a pathway conserved throughout all
classes of mammals and involved in processes such as
cell growth, neuronal survival, axonal outgrowth and
long-term plasticity [29,30]. The ERK pathway has been
proposed as a possible target for TSE therapy since sev-
eral tyrosine kinase inhibitors, such as STI571 and ima-
tinib mesylate, have recently been shown to induce a
complete clearance of PrP
Sc in ScN2a cells and a
decrease of its levels in scrapie-infected mouse spleens
[31,32]. In addition, inhibitors of the MEK 1/2 complex
have proven to be efficient in clearing PrP
Sc from
ScGT1 cells [33]. Focusing on the three key nodes of
ERK pathway, the src family, MEK1/2 and ERK1/2 com-
plexes, we found that prion replication leads to a general
hyper-activation of this cascade in GT1-1 cells. Interest-
ingly, although we detected an increased level of phos-
phorylation for the ERK complex, we also found a lower
level of activation of the MEK complex. We can specu-
late that this apparent paradox involves a different
action of some phosphatases on ERK1/2 upon chronic
prion infection.
We also examined the activation state of the pathway
in de novo infected cells to assess the role of cloning
selection in ERK signaling. We confirmed the activation
of the pathway in GT1 cells upon prion infection,
though the levels of phosphorylated proteins were not
the same as for chronic infected cells. In this case we
were able to detect increased levels for both phospho-
MEK and phospho-ERK complexes in newly infected
cells, but not for the src family. Most likely, since the
antibody we used to detect src proteins recognizes all
the 9 members of the family, the decrease in phospho-
src kinases may be explained considering the contribu-
tions of all the members of the family to the signal
detected by Western blotting. In response to acute
infection some members of the src family may undergo
a massive negative regulation in terms of phosphoryla-
tion. While the src family member fyn seems to be the
tyrosine kinase directly involved in the activation of
the ERK pathway via PrP [17], other four members of
the family (src, yes, lck and lyn) are expressed within
the CNS and act on different substrates [34]. It has been
shown that the tyrosine kinase inhibitor STI571 is able
to block prion replication in scrapie-infected cells, pro-
moting PrP
Sc clearance throughout the lysosomal path-
way [31]. Thus, it seems that the aberrant activation of
src family proteins in chronically infected cells results in
an impaired function of the lysosomal compartment,
Figure 7 Scrapie infection affects cell proliferation. Cell proliferation was evaluated in ScGT1 and GT1 cells, pre-treated for 6 days with
quinacrine (1 μM) and Fab D18 (50 nM), over 4 days by means of MTT assay. Prion infection inhibits cell proliferation and both treatments seem
to have no effect on it. Cell growth rate was calculated as described in Materials and Methods. All data come from three independent
experiments performed each one in 5 replicates; they are expressed as mean value ± SD. Statistics were performed using Student’s T-test,
*** P < 0.001.
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Sc accumulation. So, the negative regula-
t i o nu n d e r g o n eb ys o m em e m b e r so ft h es r cf a m i l y ,
when GT1 cells were exposed to prions in acute fashion,
may be interpreted as a feedback response of the cell to
induce PrP
Sc catalysis. The self-propagating nature of
prions and the foundation of a chronic infection in the
long term, may lead to the loss of this cellular response,
resulting in the aberrant activation of src kinases found
in the ScGT1 cells.
ERK retention within the cytoplasm: a possible cause for
neurodegeneration?
Taken together, these data may unveil at least one pos-
sible molecular mechanism responsible for neuronal
loss upon prion infection. Besides the archetypical
functions of the ERK cascade in cell survival and pro-
liferation, recently a novel role in regulating cell death
has emerged in neurodegenerative diseases. Phospho-
ERK aggregates were found in the substantia nigra of
Parkinson’s disease patients [35]. Elevated levels of
phospho-ERK were also revealed in brain extracts of
AD patients, but not in control individuals [36]. More-
over, a chronic activation of the ERK complex was
detected in organotypic hippocampal slides from ani-
mal models for AD overexpressing Ab [37]. In addition
to the chronic activation of ERK, its localization within
the cell seems to also play a crucial role in initiating
neurodegenerative processes [38]. An intriguing sce-
nario in which an aberrant activation of ERK, in
kinetic and spatial terms, is linked to cell death pro-
cesses seems to fit with our findings in GT1 cells,
expanding our understanding of prion diseases. Both
chronically and newly infected ScGT1 cells showed a
persistent activation of ERK. Since prion conversion
requires direct interaction between PrP
C and PrP
Sc
most likely in the amyloidogenic domain
(AGAAAAGA) of PrP (amino acids 109-122) [39], in
ScGT1 cells prion replication may lead to aberrant sig-
naling. Upon infection, the formation of multimeric
structures of PrP, such as oligomers, may trigger the
chronic activation of the ERK pathway. Immunocyto-
chemistry data seem to provide support to our model.
A different compartmentalization of phospho-ERK was
described in infected and non-infected GT1 cells.
While the active form of ERK seemed to be efficiently
translocated in the nuclear compartment of uninfected
cells, upon prion infection phospho-ERK appeared to
be preferentially retained in the cytoplasm. Moreover,
we showed how cell growth rate was lower in ScGT1
cells compared to uninfected cells. Tentatively, the
impairment of nuclear translocation in infected cells
may be correlated with the failed transcription of neu-
roprotective factors essentialf o rc e l ls u r v i v a la n dc o u l d
explain the differences found in cell proliferation. In
a d d i t i o n ,u p o np r i o ni n f e c t i o ni nG T 1c e l l s ,ah y p e r -
phosphorylation of the S6 ribosomal protein has been
described [40]. Since S6 protein is a target for the ERK
complex, further studies are needed to assess whether
the preferential localization of the active form of ERK
in the cytoplasm of scrapie-infected ScGT1 can be also
associated to the phosphorylation of S6 protein. The
lack of gross pathological phenotype in ScGT1 could
be explained by considering GT1 as active proliferating
cells. Cell divisions may dilute the amount of PrP
Sc
among daughter cells, minimizing marked pathological
effects on cell physiology. In post-mitotic neuronal
cells of the CNS, PrP
Sc can accumulate and ultimately
lead to neurodegeneration. This could explain why
subpopulations of infected ScGT1 show reduced viabi-
lity, with signs of neurodegeneration and vacuolation
[41]. For some cells, where prion conversion rate is
higher, the ERK pathway could be hyper-stimulated
and detectable cellular damages may occur.
Fab D18 and quinacrine treatments differently affect the
ERK pathway
The second aim of our study was to assess the effects on
the ERK cascade induced by two molecules known to
block prions. In recent years, much effort has been
devoted to finding a molecule that would halt prion pro-
p a g a t i o n .T od a t e ,t w oc l a s s e so fc o m p o u n d sy i e l d e d
promising results: small chemicals such as acridines [27]
and antibodies, or antibody fragments, such as Fab D18
[26]. In our study, both infected and uninfected cells
were treated with the two compounds to assess the
effect on the activation of ERK pathway. Two main
datasets emerged from our study, which revealed differ-
ent effects on the ERK pathway when comparing
infected and uninfected cells. Whilst the epitope for Fab
D18 on PrP is well known [42], the binding surface on
PrP for quinacrine is still debated. Moreover, the affinity
of Fab D18 for PrP is much higher than for quinacrine;
the dissociation constant for the quinacrine-PrP
C com-
plex is 4.6 mM [43], whereas for the Fab D18-PrP
C
complex is 1.6 nM [26]. Thus, the two compounds
might act through different mechanisms. In particular
quinacrine may interfere with prion replication through
a process that does not require its binding to PrP
C,
since the half-maximal PrP
Sc inhibition occurs at effec-
tive concentrations [EC(50)] in the micromolar range
[27]. Recent studies, for example, have shown acridines
binding directly to PrP
Sc [44]. These data may also
explain the differences found in terms of ERK pathway
activation between infected and uninfected cells after
treatment with the two compounds. Since Fab D18 car-
ries on its inhibitory activity principally through binding
to PrP
C and thus preventing its interaction with PrP
Sc,
the effects on cell signaling are similar both in ScGT1
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C expression. On
the contrary, quinacrine has a low affinity for PrP
C and
seems to block prion replication by binding and disrupt-
ing PrP
Sc fibrils [45]. Large aggregates of PrP
Sc are dis-
tinctive traits of infected cells, so it is reasonable that
the effects of quinacrine treatment on the ERK pathway
in infected and uninfected cells are very different. Alter-
natively, quinacrine might bind to protein(s) involved in
prion replication, or may alter the biochemical environ-
ment necessary for template refolding. For many years
the so-called “protein X” has been hypothesized to play
an essential role in prion replication, a protein, maybe a
chaperon, interacting with the PrP
C-PrP
Sc complex and
facilitating conversion. The binding of quinacrine to a
key site of this putative molecule may alter its normal
function in GT1 cells and interfere with the prion con-
version process.
In addition, even though quinacrine and Fab D18
seem to maintain the physiological distribution of phos-
pho-ERK in GT1 cells, both of them failed to revert
ERK phosphorylation to physiological levels upon treat-
ment of prion infected ScGT1. They also failed in rescu-
ing the impaired cell proliferation detected in ScGT1
cells. These data could be explained considering that
prion infection may alter some fundamental mechanism
involved in cell division irreversibly. As an alternative, it
could be hypothesized that the two treatments do not
block prion replication completely, but just decrease it
below the sensitivity of detection techniques. Moreover,
the ability of the two molecules to alter the localization
and the activation levels of ERK cascade in uninfected
cells should be taken into consideration as a significant
side effect in any therapeutic approach to prion disease.
The MEK inhibitor U0126 was also tested for its cell
proliferation rescuing capacity in ScGT1 cells (see addi-
tional file 1). No significant differences in terms of cell
growth were detected after 3 days of treatment, using a
concentration of drug that completely inhibited the ERK
complex phosphorylation (10 μM) (see additional file 1).
Thus, identifying a pharmacological treatment that not
only clears prion infection, but also does not carry any
apparent side effect on healthy cells, still remains a
major challenge.
Conclusions
In this study we investigated the role of prion infection
in ERK cascade signaling using a well-known neuronal
model of prion replication. For the first time we were
able to show a correlation between the aberrant activa-
tion of the ERK1/2 complex, its localization within the
cytosolic compartment, and a lower growth rate in
infected GT1 cells. Our findings indicate a possible
mechanism of neurodegeneration that might explain the
neuronal loss expressed upon prion disease onset. In
addition, we tested two prion-curing compounds for
their actions on the ERK pathway. The different
responses observed may be correlated to different
mechanisms of action.
Materials and methods
Cell lines and cell culture
GT1 and ScGT1 cells were maintained in Dulbecco’s
Modified Eagle’s Medium with 4.5 g/L glucose (DMEM)
(GIBCO/Invitrogen), supplemented with 10% v/v fetal
bovine serum (GIBCO/Invitrogen) and antibiotics (100
IU/mL penicillin and 100 mg/mL streptomycin) at 37°C
in a humidified atmosphere with 5% CO2. All cell lines
were kindly provided by Dr. P. Mellon (The Salk Insti-
tute, La Jolla, CA, USA). Scrapie cells were chronically
infected with Rocky Mountain Lab (RML) prion strain
according to already published procedures.
De novo prion infection
ScGT1 cells were grown at confluence and fixed in par-
aformaldehyde 4% in PBS for 20 min at room tempera-
ture (RT). Then, the cell layer was washed in PBS three
times and permeabilized with TRITON XT-100 0.1% in
PBS for 15 min. After further washings with PBS, GT1
cells were cultured on this “infective layer” for 1 week,
refreshing the medium on the third day. Then cells
were split 1:3 for three times and tested at the fourth
passage. Cells were grown on fixed GT1 cells as control.
Antibodies
The monoclonal antibodies against the phosphorylated
and non-phosphorylated forms of the src family [Src
Family Antibody #2109 and phospho-Src Family
(Tyr416) antibody #2101), MEK1/2 (MEK1/2 Antibody
#9122 and phospho-MEK1/2 (Ser217/221) (41G9) rabbit
mAb #9154] and ERK 1/2 [p42 MAP Kinase (3A7)
mouse mAb #9107 and phospho-p44/42 Map Kinase
(Thr202/Tyr204) Ab #9101] were purchased from Cell
Signaling Technology. The Fab D18 fragment raised
against PrP was purchased from InPro Biotech.
Preparation of cytosolic extracts
Cells were treated for 6 days with Fab D18 (50 nM), or
quinacrine (Fluka), which had been dissolved in PBS (1
μM). The medium was refreshed after 3 days. Cells
were then washed twice with cold PBS 1× (GIBCO/
Invitrogen) and incubated for 10 min on ice, in lysis
buffer [50 mM Tris-HCl (pH 7.4) 150 mM NaCl, 1%
Triton X-100, 2 mM Na3VO4 and a mixture of pro-
tease inhibitors (Roche)]. The cell extracts were then
centrifuged at 2,300 g for 5 min. The supernatant was
stored at -80°C before being used. Total protein con-
centration was determined using the bicinchoninic acid
assay (Pierce).
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Cells were washed twice with cold PBS 1× (GIBCO/Invi-
trogen) and lysed with lysis buffer (10 mM Tris-HCl pH
8.0, 150 mM NaCl, 0.5% nonidet P-40 substitute, 0.5%
deoxycholic acid sodium salt) and pelleted by centrifu-
gation at 2,300 g for 5 min. The supernatant was col-
lected and the total protein concentration measured
using bicinchoninic acid assay (Pierce). For the assay,
250 μg of protein was treated with 5 μgp r o t e i n a s eK
(Roche, ratio protein:protease 50:1) for 1 hour at 37°C.
Digestion was stopped by the addition of phenylmethyl
sulphonyl fluoride to a final concentration of 2 mM.
The PrP was precipitated by ultracentrifugation at
100,000 g (Optima TL, Beckman) for 1 hour at 4°C.
After centrifugation, the supernatant was discarded and
the pellet resuspended in loading buffer 1X, before load-
ing onto a 12% SDS-PAGE. Samples were electroblotted
onto membranes of polyvinylidene fluoride (PVDF).
PVDF membranes were blocked with 5% (w/v) non-fat
milk protein in TBS-T (0.05% Tween) for 1 hour at RT.
Membranes were incubated in 1 μg/mL of Fab D18 in
1× PBS for 2 hours at RT; before incubation for 1 hour,
in the secondary antibody, goat-anti-human HRP-conju-
g a t e d( P i e r c e ) ,a t1 : 5 0 0 0d i l u t e di n5 %( w / v )n o n - f a t
m i l kp r o t e i ni nT B S - T .A f t e rs e v e r a lw a s h e s ,t h es i g n a l
was detected using ECL kit (Amersham Pharmacia) on
ECL Hypermax films (Amersham Pharmacia).
Western blot assay
An amount equal to 25 μg of total proteins was separated
by 12% SDS-PAGE and transferred to PVD membranes
(Millipore). These were then blocked in 5% non-fat dried
milk in TBS-T (0.05% Tween) for 1 hour at RT before
incubation overnight at 4°C with primary antibody
(1:1,000 or 1:2,000) diluted in 5% non-fat dried milk or
5% bovine serum albumin. After 3 washes in TBS-T, the
membranes were incubated for 1 hour at RT in second-
ary antibody, goat-anti-mouse or rabbit, HRP-conjugated
(1:2,000) diluted in 5% non-fat dried milk in TBS-T. The
chemiluminescent signal was detected using ECL kit
(Amersham Pharmacia) on ECL Hypermax films (Amer-
sham Pharmacia). Densitometric analysis was performed
using a Molecular Imager ChemiDoc XRS System
equipped with Quantity One software (Biorad).
Thiazolyl blue tetrazolium bromide (MTT) cell growth
assay
ScGT1 and GT1 cells were treated with quinacrine
(1 μM )a n dF a bD 1 8( 5 0n M )f o r6d a y s .T h e n ,a b o u t
30,000 cells per well were cultured, again in the pre-
sence of the two compounds at the same concentrations
in a 96-well, tissue culture-treated plate for 4 days, mea-
suring cell proliferation each day. To study the effects of
the MEK inhibitor U0126 (Promega) on cell growth,
ScGT1 and GT1 cells were seeded in a 96-well, tissue
culture-treated plate and treated with U0126 (10 μM)
diluted in dimethyl sulfoxide (DMSO) for 3 days.
DMSO alone was used as control. In all conditions
tested, every 24 hours the medium was removed and
the cells were incubated with 150 μL of MTT (Sigma)
working solution (0.5 mg/mL of MTT in sterile PBS) for
2 hours at 37°C. The solution was removed and forma-
zan was solubilized adding 150 μL of DMSO to each
well. The optical density was read at 560 nm and the
background subtracted at 670 nm using a VersaMax
plate reader (Molecular Device). Growth rate was calcu-
lated dividing the absorbance value of the last day with
the value measured on the first.
Immunofluorescence assay
Treated and untreated cells were grown overnight on
glass coverslips coated with poly-L-lysine (10 μg/mL)
before fixation in paraformaldehyde 4% in PBS for 20
min at RT. The cells were blocked for 1 hour at RT, in
10% normal goat serum (VECTOR Laboratories) diluted
in PBS with 0.3% Triton X-100. After blocking, cells
were incubated at 4°C overnight with primary antibody
in dilution buffer (1% bovine serum albumin in PBS
with 0.3% Triton X-100). Coverslips were washed 2
times in PBS and given an additional third washing in
high-salt PBS for 2 min to decrease the aspecific binding
of the antibody. After an additional wash with PBS
alone, cells were further incubated for 1 hour at RT in
the dark with secondary antibody, conjugated with Alex-
aFluor 488 (1:500; Invitrogen) in dilution buffer. Cells
were further washed as described above, before mount-
ing on Vectashield with DAPI (VECTOR Laboratories).
Images were acquired with a DMIR2 confocal micro-
scope equipped with Leica Confocal Software (Leica).
Fluorescence quantification
In order to quantify the fluorescence in the cytosolic
and nuclear compartments, random fields for each
tested condition were taken at the same magnification
(40×, zoom 4×). Then, a region of interest (ROI) with
an area of 144 pixels (12 × 12) was chosen, and the
average intensity of fluorescence within the ROI was
measured in the nucleus and cytosol of every cell pre-
sent in the field. More than 100 cells for every condition
were analyzed. The values obtained were averaged, and
the ratios between the mean value for the cytosol and
t h em e a nv a l u ef o rt h en u c l e u sw e r ep l o t t e di nah i s t o -
gram graph. Images were analyzed with ImageJ open
source software http://rsbweb.nih.gov/ij/index.html. The
results were obtained from three independent
experiments.
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Student’s t test was used to determine significant differ-
ences among the src family, MEK 1/2, ERK 1/2 phos-
phorylation, among prion infected and uninfected, and
between Fab D18 treated and quinacrine treated cell
lines. The levels of phosphorylation for every protein
were normalized to the total amount of the same pro-
tein. All data are expressed as mean value ± SD and the
values of controls are adjusted to 1; each resulting value
was determined by averaging three independent
experiments.
Additional material
Additional file 1: MEK inhibitor U0126 has no effect on cell
proliferation. ScGt1 and GT1 cells were treated for 3 days with MEK
inhibitor (10 μM in DMSO) and its effects on cell proliferation were
evaluated by means of MTT assay. The inhibitory effect on MEK
phosphorylation at the concentration used was tested by Western blot
(A). A complete inhibition of MEK phosphorylation was detected already
after 1 hour of treatment with U0126 (10 μM) both in ScGT1 and GT1.
The treatment conducted over 3 days on infected and uninfected cells
had no statistically significant effect on cell proliferation (B). Cell growth
rate was calculated as described in the Materials and Methods section.
All data come from three independent experiments performed each one
in 5 replicates; they are expressed as mean value ± SD.
Abbreviations used
PrP: prion protein; PrP
C: cellular form of PrP; PrP
Sc: scrapie isoform of PrP;
N2a: mouse neuroblastoma cell line; ScN2a: scrapie-infected N2a; GT1:
mouse hypothalamic cell line; ScGT1: scrapie-infected GT1; PK: proteinase K;
MAPK: mitogen activated protein kinase; MEK: MAP and ERK kinases; ERK:
extracellular regulated kinase.
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